GILD · NASDAQ · STOCK
Gilead Sciences (GILD) Stock Analysis
$147.51
52W $108.46 – $157.29
57/100
$178.09B
-55.2
0.34
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is GILD Bullish or Bearish?
Bullish.
Innellis AI committee rates Gilead Sciences (GILD) Buy with a composite score of 57/100
, based on 5 analysts with 40% agreement.
Last updated August 19, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.48 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.52 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — price-to-book of 6.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 4.0% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 6.7x prices in significant intangible value — Value
- ROE of only -16.3% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 72 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 19, 2026
Overall Committee Score
57/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 75%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 4.0% pays you to wait
− Price-to-book of 6.7x prices in significant intangible value
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 72 is in overbought territory
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2974.99)
Investment Thesis Evolution
Committee score moved marginally from 56.5 to 56.5.
Comparing 2026-08-18 to 2026-08-19 (1 day apart).
Technical Analysis
RSI (14)
81.1
Overbought
MACD Histogram
0.928
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$127.64
Resistance
$157.26
Bollinger %B
1.15
Above Upper Band
Price vs Moving Averages
EMA 9
$137.45
Above
EMA 21
$134.80
Above
EMA 50
$132.87
Above
EMA 200
$129.74
Above
Fundamental Analysis
Valuation
67
Growth
40
Profitability
75
Financial Health
26
Cash Flow
70
Valuation
P/E Ratio
-55.2×
P/B Ratio
15.07×
PEG Ratio
0.36
Dividend Yield
2.24%
52W High
$157.29
52W Low
$108.46
Quality & Growth
ROE
3748.6%
ROA
1441.8%
Gross Margin
7958.7%
Operating Margin
-490.2%
Revenue Growth YoY
—
Debt / Equity
2.22
AI Fundamental Assessment
P/E ratio of -55.2 (inexpensive relative to a 15-40x range); Price-to-book of 15.1x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 37.5%; Return on assets of 14.4%; Net margin of -10.6%; Gross margin of 79.6%; Current ratio of 1.27 (tight short-term liquidity); Debt-to-equity of 2.22; Free cash flow per share is positive (10.62); Most recent quarter beat estimates by 8.5%; 5 consecutive earnings beats; EPS growth decelerating (+9.1% -> -432.5% QoQ); Average YoY EPS growth of -435.8%; Analyst estimates falling over recent quarters
Get the Full GILD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →